Laura Lin is currently the Head of Biomedicine Design at Pfizer, a position they have held since 2025 in Cambridge, Massachusetts. Previously, they served as Vice President of Biomedicine Design, focusing on biotherapeutics engineering and molecular assessment. Laura undertook postdoctoral research at MIT from 1994 to 1996, where they studied RNA/Protein interactions under the mentorship of Prof. Paul Schimmel. Prior to their current role, they held multiple positions at Pfizer, including Principal Research Scientist III, Senior Director of Global BioTherapeutic Technologies, and Executive Director of BioMed Design, contributing extensively to protein biochemistry and structural biology. Laura earned a Ph.D. in Biophysics from New York University in 1994.
This person is not in any teams
This person is not in any offices